Cargando…
Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity
INTRODUCTION: Dysregulated activity of matrix metalloproteinases (MMPs) drives a variety of pathophysiological conditions. Non-invasive imaging of MMP activity in vivo promises diagnostic and prognostic value. However, current targeting strategies by small molecules are typically limited with respec...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085681/ https://www.ncbi.nlm.nih.gov/pubmed/34750717 http://dx.doi.org/10.1007/s11307-021-01668-z |
_version_ | 1784703871649579008 |
---|---|
author | Honold, Lisa Austrup, Melanie Faust, Andreas Konken, Christian Paul Schwegmann, Katrin Zinnhardt, Bastian Daniliuc, Constantin Gabriel Haufe, Günter Schäfers, Michael Kopka, Klaus Hermann, Sven |
author_facet | Honold, Lisa Austrup, Melanie Faust, Andreas Konken, Christian Paul Schwegmann, Katrin Zinnhardt, Bastian Daniliuc, Constantin Gabriel Haufe, Günter Schäfers, Michael Kopka, Klaus Hermann, Sven |
author_sort | Honold, Lisa |
collection | PubMed |
description | INTRODUCTION: Dysregulated activity of matrix metalloproteinases (MMPs) drives a variety of pathophysiological conditions. Non-invasive imaging of MMP activity in vivo promises diagnostic and prognostic value. However, current targeting strategies by small molecules are typically limited with respect to the bioavailability of the labeled MMP binders in vivo. To this end, we here introduce and compare three chemical modifications of a recently developed barbiturate-based radiotracer with respect to bioavailability and potential to image MMP activity in vivo. METHODS: Barbiturate-based MMP inhibitors with an identical targeting unit but varying hydrophilicity were synthesized, labeled with technetium-99m, and evaluated in vitro and in vivo. Biodistribution and radiotracer elimination were determined in C57/BL6 mice by serial SPECT imaging. MMP activity was imaged in a MMP-positive subcutaneous xenograft model of human K1 papillary thyroid tumors. In vivo data were validated by scintillation counting, autoradiography, and MMP immunohistochemistry. RESULTS: We prepared three new (99m)Tc‐labeled MMP inhibitors, bearing either a glycine ([(99m)Tc]MEA39), lysine ([(99m)Tc]MEA61), or the ligand HYNIC with the ionic co-ligand TPPTS ([(99m)Tc]MEA223) yielding gradually increasing hydrophilicity. [(99m)Tc]MEA39 and [(99m)Tc]MEA61 were rapidly eliminated via hepatobiliary pathways. In contrast, [(99m)Tc]MEA223 showed delayed in vivo clearance and primary renal elimination. In a thyroid tumor xenograft model, only [(99m)Tc]MEA223 exhibited a high tumor-to-blood ratio that could easily be delineated in SPECT images. CONCLUSION: Introduction of HYNIC/TPPTS into the barbiturate lead structure ([(99m)Tc]MEA223) results in delayed renal elimination and allows non-invasive MMP imaging with high signal-to-noise ratios in a papillary thyroid tumor xenograft model. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01668-z. |
format | Online Article Text |
id | pubmed-9085681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-90856812022-05-11 Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity Honold, Lisa Austrup, Melanie Faust, Andreas Konken, Christian Paul Schwegmann, Katrin Zinnhardt, Bastian Daniliuc, Constantin Gabriel Haufe, Günter Schäfers, Michael Kopka, Klaus Hermann, Sven Mol Imaging Biol Research Article INTRODUCTION: Dysregulated activity of matrix metalloproteinases (MMPs) drives a variety of pathophysiological conditions. Non-invasive imaging of MMP activity in vivo promises diagnostic and prognostic value. However, current targeting strategies by small molecules are typically limited with respect to the bioavailability of the labeled MMP binders in vivo. To this end, we here introduce and compare three chemical modifications of a recently developed barbiturate-based radiotracer with respect to bioavailability and potential to image MMP activity in vivo. METHODS: Barbiturate-based MMP inhibitors with an identical targeting unit but varying hydrophilicity were synthesized, labeled with technetium-99m, and evaluated in vitro and in vivo. Biodistribution and radiotracer elimination were determined in C57/BL6 mice by serial SPECT imaging. MMP activity was imaged in a MMP-positive subcutaneous xenograft model of human K1 papillary thyroid tumors. In vivo data were validated by scintillation counting, autoradiography, and MMP immunohistochemistry. RESULTS: We prepared three new (99m)Tc‐labeled MMP inhibitors, bearing either a glycine ([(99m)Tc]MEA39), lysine ([(99m)Tc]MEA61), or the ligand HYNIC with the ionic co-ligand TPPTS ([(99m)Tc]MEA223) yielding gradually increasing hydrophilicity. [(99m)Tc]MEA39 and [(99m)Tc]MEA61 were rapidly eliminated via hepatobiliary pathways. In contrast, [(99m)Tc]MEA223 showed delayed in vivo clearance and primary renal elimination. In a thyroid tumor xenograft model, only [(99m)Tc]MEA223 exhibited a high tumor-to-blood ratio that could easily be delineated in SPECT images. CONCLUSION: Introduction of HYNIC/TPPTS into the barbiturate lead structure ([(99m)Tc]MEA223) results in delayed renal elimination and allows non-invasive MMP imaging with high signal-to-noise ratios in a papillary thyroid tumor xenograft model. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01668-z. Springer International Publishing 2021-11-08 2022 /pmc/articles/PMC9085681/ /pubmed/34750717 http://dx.doi.org/10.1007/s11307-021-01668-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Honold, Lisa Austrup, Melanie Faust, Andreas Konken, Christian Paul Schwegmann, Katrin Zinnhardt, Bastian Daniliuc, Constantin Gabriel Haufe, Günter Schäfers, Michael Kopka, Klaus Hermann, Sven Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity |
title | Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity |
title_full | Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity |
title_fullStr | Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity |
title_full_unstemmed | Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity |
title_short | Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity |
title_sort | towards optimized bioavailability of (99m)tc-labeled barbiturates for non-invasive imaging of matrix metalloproteinase activity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085681/ https://www.ncbi.nlm.nih.gov/pubmed/34750717 http://dx.doi.org/10.1007/s11307-021-01668-z |
work_keys_str_mv | AT honoldlisa towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT austrupmelanie towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT faustandreas towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT konkenchristianpaul towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT schwegmannkatrin towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT zinnhardtbastian towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT daniliucconstantingabriel towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT haufegunter towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT schafersmichael towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT kopkaklaus towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity AT hermannsven towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity |